More than 100 million acquisition of Huaji pharmaceutical and extension of traditional Chinese medicine industry chain

Since this year, Duyiwei (002219, stock bar) has staged a series of mergers and acquisitions, and the enthusiasm for military expansion is still rising Yesterday evening, the company announced that it had signed the equity transfer agreement with Li Tuo, Li Nie Wei and Cao Zuobin on November 6 The company transferred 100% equity of Sichuan Huaji Pharmaceutical Co., Ltd (hereinafter referred to as "Huaji pharmaceutical") with its own capital of 101 million yuan According to the data, Huaji pharmaceutical has a registered capital of 8 million yuan, mainly engaged in the production and sales of Chinese herbal pieces, toxic Chinese herbal pieces and agricultural and sideline products As of August 31, 2013, its total assets were 53.4676 million yuan, its net assets were 13.847 million yuan, its revenue from January to August was 29.2793 million yuan, and its net profit was 5.9843 million yuan In 2012, the annual operating revenue was 14.551 million yuan, and the good performance of the net profit was 1.599 million yuan, which was the driving force for the expansion Du Yiwei announced the results of the third quarter in the evening of October 25 that the net profit attributable to the owners of the parent company in the first three quarters was 137 million yuan, an increase of 157.22% over the same period of last year; the operating revenue was 422 million yuan, an increase of 63.93% over the same period of last year; among them, the net profit attributable to the owners of the parent company in the third quarter was 32698600 yuan, an increase of 74.69% over the same period of last year; the operating revenue was 110 million yuan, an increase of 74.69% over the same period of last year The year-on-year increase was 19.34% Du Yiwei said that the acquisition is an extension of the company's traditional Chinese medicine industry chain and is based on the company's strategic requirements for the development of the traditional Chinese medicine herbal medicine industry and the layout of large health industry, which is conducive to improving the company's industrial layout and enhancing the company's overall strength and market competitive advantage In addition, Huaji pharmaceutical completed GMP certification in November 2010, trial production in the first half of 2011, and officially put into production in the third quarter of 2011 It is actively exploring the market of Chinese herbal pieces So far, it has established more than 20 customer channels, including the Affiliated Hospital of Chengdu University of traditional Chinese medicine For the acquisition, according to the Research Report of securities companies, the target company of the acquisition is mainly engaged in the production and sales of Chinese herbal pieces, and has established more than 20 customer channels, such as the Affiliated Hospital of Chengdu University of traditional Chinese medicine, with a significant increase in business performance In combination with the support policies for the development of the national traditional Chinese medicine industry and the good market prospects of Chinese herbal pieces, Huaji pharmaceutical will increase its efforts to expand the market of Chinese Herbal Pieces in the future, and at the same time will increase the business of Chinese herbal medicine management and Chinese herbal extraction The acquisition of the company will help the company to extend the current Chinese medicine industry chain, enter the Chinese medicine beverage industry, and lay out a healthy industrial pattern At the same time, it will enhance the company's overall strength and market competitive advantage, enhance the company's profit potential, and have a positive impact on the company's current and future financial situation and operating results In addition, Duyiwei also actively arranged private hospitals According to the statistics of the first financial daily, at present, the private hospitals it acquired include Qionglai Welfare Hospital, Deyang Meihao tomorrow hospital Co., Ltd., Ziyang jianshunwang physical examination hospital Co., Ltd., Pengxi jianshunwang traditional Chinese medicine (orthopedics) hospital Co., Ltd and Chengdu Ping'an hospital tumor diagnosis and treatment Co., Ltd There are five centers with 85% operating income right in 15 years.